Keuangan Vaxcyte, Inc. (PCVX)
NASDAQ · Healthcare · Biotechnology · Karyawan: 507 · CEO: Grant E. Pickering
- Harga
- $62,03 -0,93%
- Kapitalisasi pasar
- $9,76 M
- Nilai perusahaan
- $9,7 M
- Laporan terakhir
- Q2 '26 diajukan 2026-08-05
- Laporan berikutnya
- 2026-11-03 Estimasi EPS: -$2,11
Pendapatan (TTM)$0– vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)–– vs tahun laluLaba operasional: -$1,17 M
Laba bersih (TTM)-$1,06 M-94,4% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)-$1,2 M-124,8% vs tahun laluCapex: $40,6 jt
EPS dilusian (TTM)-$7,64-81,5% vs tahun laluJumlah 4 kuartal terakhir
Kas neto$1,37 M-13,0% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $9,76 M EV $9,7 M
- Pendapatan
- $0 12 bulan terakhir
- Pertumbuhan pendapatan
- – Konsensus FY2026
- Margin laba
- – Laba bersih / pendapatan, TTM
- P/E
- -8,1× Forward -7,5× (FY2026)
- P/S
- 0,0× Harga / penjualan, TTM
- EV / EBITDA
- -9,2× TTM
- Arus kas bebas
- -$1,2 M 12 bulan terakhir
- Laba bersih
- -$1,06 M 12 bulan terakhir
- Estimasi pendapatan
- $25 jt Konsensus FY2026
- Laba
- 2026-11-03 Estimasi pendapatan: $12,5 jt
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-05): pendapatan n/a, EPS melampaui 4,4%Pendapatan – vs $12,5 jt yang diharapkan (–); EPS -$1,97 vs -$2,06 (+4,4%).
- Jumlah saham dilusian naik dalam setahun: 6,2%Saham dilusian pada Q2 '26: 144 jt, setahun sebelumnya: 136 jt.
- Kas neto: $1,37 MKas + investasi jangka pendek: $1,49 M, utang termasuk sewa: $115 jt; tahun lalu kas neto: $1,58 M.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $0 | $0 | – |
| Laba operasional | -$303 jt | -$226 jt | -33,8% |
| Laba bersih | -$284 jt | -$167 jt | -70,7% |
| EPS dilusian | -$1,97 | -$1,22 | -61,5% |
| Arus kas operasional | -$513 jt | -$121 jt | -323,5% |
| Capex | $19,4 jt | -$19,5 jt | +199,2% |
| Arus kas bebas | -$532 jt | -$102 jt | -423,8% |
| R&D | $268 jt | $194 jt | +37,9% |
| Kompensasi berbasis saham | $79,2 jt | $36,9 jt | +114,5% |
Dilaporkan vs konsensus
2026-08-05| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| EPS (basis konsensus) | -$1,97 | -$2,06 | +4,4% |
Dari laporan 2026-08-05 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '22 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Pneumococcal Conjugate Vaccine | $7 M | 0,0% | 100,0% | $21 M | 0,0% |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- -$1,16 M
- Capex
- -$40,6 jt
- Buyback
- $0
- Dividen
- $0
- Akuisisi
- $0
- Utang neto diterbitkan
- $0
- Kompensasi berbasis saham
- $188 jt
- Arus kas bebas
- -$1,2 M
- Dikembalikan ke pemegang saham / FCF
- 0,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -8,1× | – | – |
| EV / EBITDA | -9,2× | – | – |
| EV / Penjualan | 0,0× | – | – |
| Harga / FCF | -8,1× | – | – |
| Harga / Nilai buku | 3,2× | 3,6× | 2,3× – 4,9× |
| Imbal hasil FCF | -12,3% | -7,5% | -10,7% – -4,8% |
| Imbal hasil modal yang diinvestasikan | -40,6% | -28,9% | -36,9% – -16,9% |
| Imbal hasil ekuitas | -37,6% | -26,7% | -35,2% – -14,0% |
Analis
Target konsensus $122,33 (+97,2%)
rentang $120,00 – $125,00 · peringkat Buy
Beli kuat0
Beli11
Tahan0
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $25 jt | – | -$8,23 | -46,1% | -7,5× | 6 |
| FY2027 | $87,1 jt | +248,6% | -$6,50 | +21,0% | -9,5× | 6 |
| FY2028 | $97,9 jt | +12,4% | -$6,44 | +1,0% | -9,6× | 6 |
| FY2029 | $1,41 M | +1.339,3% | $0,74 | +111,6% | 83,4× | 3 |
| FY2030 | $2,2 M | +56,0% | $5,18 | +596,9% | 12,0× | 2 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 172 angka yang ditandai Vaxcyte, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $101 jt | $31,4 jt | +221,3% | $70,9 jt | $48,5 jt | +46,3% |
| Accretion (Amortization) of Discounts and Premiums, Investments | $1,18 jt | $4,49 jt | -73,7% | $14,4 jt | $38,7 jt | -62,7% |
| Accrued Liabilities, Current | $24,7 jt | $32,2 jt | -23,2% | $31,1 jt | $29,1 jt | +6,7% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $32,8 jt2025-12-31 | $16,3 jt | +101,4% | $32,8 jt | $16,3 jt | +101,4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$7,55 jt | -$1,89 jt | -299,9% | $1,59 jt | -$3,87 jt | +141,0% |
| Additional Paid in Capital, Common Stock | $5,53 M | $4,77 M | +15,9% | $4,84 M | $4,7 M | +3,0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 15,4 jt | 13,3 jt | +16,2% | 14,5 jt | 11,6 jt | +25,1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $41,2 jt | $36,9 jt | +11,7% | $139 jt | $84,8 jt | +63,7% |
| Assets | $3,14 M | $3,31 M | -5,1% | $3 M | $3,51 M | -14,5% |
| Assets, Current | $1,55 M | $1,72 M | -9,5% | $1,63 M | $1,79 M | -9,0% |
| Assets, Noncurrent | $1,59 M | $1,59 M | -0,3% | $1,38 M | $1,72 M | -20,2% |
| Capital Expenditures Incurred but Not yet Paid | -$1,68 jt | -$418 rb | -302,9% | $7,54 jt | $13,2 jt | -42,8% |
| Cash and Cash Equivalents, at Carrying Value | $183 jt | $307 jt | -40,3% | $174 jt | $388 jt | -55,2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $185 jt | $308 jt | -40,1% | $175 jt | $389 jt | -54,9% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$77,7 jt | -$40,1 jt | -93,6% | -$214 jt | -$9,36 jt | -2.184,1% |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,46 jt2026-03-31 | 3,5 jt | +56,1% | – | – | – |
| Common Stock, Dividends, Per Share, Declared | – | – | – | $0,00 | $0,00 | – |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 500 jt | 500 jt | 0,0% | 500 jt | 500 jt | 0,0% |
| Common Stock, Shares, Issued | 145 jt | 130 jt | +11,5% | 131 jt | 125 jt | +4,9% |
| Common Stock, Shares, Outstanding | 145 jt | 130 jt | +11,5% | 131 jt | 125 jt | +4,9% |
| Common Stock, Value, Issued | $148 rb | $133 rb | +11,3% | $134 rb | $128 rb | +4,7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$285 jt | -$168 jt | -69,5% | -$761 jt | -$468 jt | -62,7% |
| Debt Securities, Available-for-sale | $2,32 M | $2,52 M | -7,7% | $2,27 M | $2,75 M | -17,4% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | $427 jt | $4,1 jt | +10.312,2% | $120 jt | $10,5 jt | +1.044,8% |
| Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months | $7,4 jt | – | – | – | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | $1,02 M | $1,17 M | -12,4% | $882 jt | $1,39 M | -36,5% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $1,3 M | $1,35 M | -3,8% | $1,39 M | $1,36 M | +2,0% |
| Debt Securities, Available-for-sale, Unrealized Loss Position | $1,8 M | $1,3 M | +38,5% | $300 jt | $1,5 M | -80,0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $27,3 jt2025-12-31 | $29,3 jt | -6,5% | $27,3 jt | $29,3 jt | -6,5% |
| Deferred Tax Assets, Gross | $689 jt2025-12-31 | $468 jt | +47,1% | $689 jt | $468 jt | +47,1% |
| Deferred Tax Assets, in Process Research and Development | $221 jt2025-12-31 | $155 jt | +42,4% | $221 jt | $155 jt | +42,4% |
| Deferred Tax Assets, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Net of Valuation Allowance | $43,2 jt2025-12-31 | $22 jt | +96,8% | $43,2 jt | $22 jt | +96,8% |
| Deferred Tax Assets, Operating Loss Carryforwards | $336 jt2025-12-31 | $196 jt | +71,6% | $336 jt | $196 jt | +71,6% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $38,3 jt2025-12-31 | $26,7 jt | +43,3% | $38,3 jt | $26,7 jt | +43,3% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $22,8 jt2025-12-31 | $14,7 jt | +55,6% | $22,8 jt | $14,7 jt | +55,6% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other | $6,47 jt2025-12-31 | $14,6 jt | -55,8% | $6,47 jt | $14,6 jt | -55,8% |
| Deferred Tax Assets, Valuation Allowance | $645 jt2025-12-31 | $446 jt | +44,7% | $645 jt | $446 jt | +44,7% |
| Deferred Tax Liabilities, Gross | $43,2 jt2025-12-31 | $22 jt | +96,8% | $43,2 jt | $22 jt | +96,8% |
| Deferred Tax Liabilities, Leasing Arrangements | $34,7 jt2025-12-31 | $21,5 jt | +61,1% | $34,7 jt | $21,5 jt | +61,1% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $1,3 jt2025-12-31 | $456 rb | +184,0% | $1,3 jt | $456 rb | +184,0% |
| Depreciation, Depletion and Amortization | $3 jt | $2,88 jt | +4,3% | $16,4 jt | $7 jt | +134,1% |
| Depreciation, Depletion and Amortization, Nonproduction | – | – | – | $16,4 jt | $7 jt | +134,3% |
| Earnings Per Share, Basic | -$1,97 | -$1,22 | -61,5% | -$5,63 | -$3,80 | -48,2% |
| Earnings Per Share, Diluted | -$1,97 | -$1,22 | -61,5% | -$5,63 | -$3,80 | -48,2% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1,4 jt | $800 rb | +74,6% | $2,44 jt | $426 rb | +472,5% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$161 jt | -$97,4 jt | -65,0% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 21,0% | 21,0% | 0,0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $140 jt | $109 jt | +28,6% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -18,2% | -23,4% | +22,2% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | – | – | – | $3,27 jt | $2,11 jt | +55,0% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | – | – | – | -0,4% | -0,5% | +20,0% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | – | – | – | $3,09 jt | -$18,5 jt | +116,7% |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | – | – | – | -0,4% | 4,0% | -110,0% |
| Effective Income Tax Rate Reconciliation, Percent | – | – | – | 0,0% | 0,0% | – |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | – | – | – | -$29 rb | $65 rb | -144,6% |
| Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | – | – | – | 0,0% | 0,0% | – |
| Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | – | – | – | $8,71 jt | $11,3 jt | -22,9% |
| Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | – | – | – | -1,1% | -2,4% | +54,2% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-02